United Therapeutics Q3 2026 Revenue Up 4%, Net Income Falls 24%
United Therapeutics (UTHR) reported Q3 2026 revenue of $832.5M, up 4% YoY, but net income fell 24% to $258.6M due to higher R&D spending and competitive pressures. EPS declined 20% to $5.71. Tyvaso DPI sales rose 13%, while nebulized Tyvaso fell 12%. R&D expenses surged 119% to $279.2M, partly due to the Thymmune acquisition. The company repurchased shares under a 10b5-1 plan and a $2B repurchase program.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger a sell‑off, but the ongoing share buyback program could mitigate downside pressure.
Market read
First‑report earnings data for a mid‑cap biotech; relevant for sector traders and earnings‑focused investors.
What to watch
The new $2.0 bn share repurchase program may provide floor support for the stock.
Background
United Therapeutics disclosed its Q3 2026 financial results, highlighting revenue growth, a steep net income decline, and increased R&D spending.
Ticker impact
United Therapeutics reported Q3 2026 earnings with revenue up 4% but net income down 24%, indicating profit pressure.
likely downside as market prices in lower earnings and higher costs
The sharp drop in net income and increased R&D spend are fresh data that typically weigh on the stock.
Market effects
Biopharma earnings pressure may affect peer valuations in the pulmonary/rare disease space.
U.S. biotech sector sees modest pullback following the report.
Limited to investors tracking U.S. biotech earnings; no broader macro impact.
Counterpoint
The revenue growth and expanded pipeline could support a longer-term upside despite short-term profit dip.
Key entities
- companyUnited Therapeutics Corporation
Biopharma firm reporting Q3 2026 earnings.
